Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Document Type
Year range
BMC Womens Health ; 21(1): 398, 2021 11 30.
Article in English | MEDLINE | ID: covidwho-1546777


OBJECTIVE: To study knowledge regarding genitourinary syndrome of menopause (GSM) and the treatments for it and to analyze treatment adherence during the COVID-19 confinement. METHODS: Multi-center observational study including women between 35 and 75 years. An extension study of treatment adherence was conducted during the coronavirus pandemic between March and April 2020. RESULTS: A sample of 2355 women were included. Vaginal dryness was the most frequently identified symptom (74.3%). Lubricants were the best-known treatments (69.6%), followed by local estrogens (25.7%); 66% of the women did not speak to their gynecologist about sexuality. Comparative analyses were conducted according to age, menopausal status, type of menopause, place of residence, type of health care received and level of education. During the coronavirus confinement period, adherence to treatments for vulvovaginal atrophy was poor in 72.5% asked (n = 204). Reduced sexual activity (p > 0.001) and coronavirus diagnosis (p = 0.003) were significantly associated with poorer treatment compliance. CONCLUSIONS: There is great lack of knowledge of the treatments used for GSM. Most women do not talk to their gynecologist about sexuality. Adherence to treatments during the coronavirus confinement has been worryingly low.

COVID-19 , Atrophy , Female , Humans , Menopause , SARS-CoV-2 , Vagina/pathology
J Obstet Gynaecol Can ; 42(3): 301-303, 2020 Mar.
Article in English | MEDLINE | ID: covidwho-1291550


Vulvovaginal atrophy (VVA) resulting from estrogen deprivation at menopause often results in distressing vaginal dryness and dyspareunia. Fewer than 25% of affected women seek help for this condition citing embarrassment, cultural values, an aging or unavailable partner and concerns about use of estrogens following the Women's Health Initiative. Available non-hormonal treatments, such as moisturizers, while affording some relief can be messy to apply and do not prevent disease progression. A new oral selective estrogen receptor modulator, ospemifene, has been found to have strong estrogenic activity in vaginal tissues without adverse estrogenic effects at other sites.

Atrophy/drug therapy , Menopause , Selective Estrogen Receptor Modulators/administration & dosage , Tamoxifen/analogs & derivatives , Vagina/drug effects , Vulva/drug effects , Aged , Atrophy/pathology , COVID-19/drug therapy , Dyspareunia/drug therapy , Female , Humans , Menopause/physiology , Middle Aged , Postmenopause , Selective Estrogen Receptor Modulators/therapeutic use , Tamoxifen/administration & dosage , Tamoxifen/therapeutic use , Vagina/pathology , Vulva/pathology